Mon, May 12, 12:07 PM (63 days ago)
**UroGen Pharma Ltd. (URGN) Q1 2025 Financial Summary** **Revenue & Profit Margins:** - **Revenue:** $20.3 million (up 7.2% YoY) - **Cost of Revenue:** $2.3 million (up 32.5% YoY) - **Gross Profit:** $17.9 million (up 5.3% YoY) - **Operating Loss:** $36.9 million (up 43.6% YoY) - **Net Loss:** $43.8 million (up 35.8% YoY) **Cash Flow:** - **Net Cash Used in Operating Activities:** $42.0 million (up 32.5% YoY) - **Net Cash Used in Investing Activities:** $25.9 million (vs. $13.5 million inflow YoY) - **Net Cash Provided by Financing Activities:** $34,000 (vs. $54.7 million YoY) **Earnings Changes:** - **Revenue Growth:** Driven by underlying demand for Jelmyto, partially offset by higher revenue reserves. - **Operating Loss Increase:** Due to higher operating expenses, including commercial preparation activities for UGN-102 and increased commercial operation costs. **Quarterly Performance Discussion:** - **Revenue:** $20.3 million (up 7.2% YoY) - **Operating Expenses:** $54.8 million (up 27.6% YoY) - **Net Loss:** $43.8 million (up 35.8% YoY) **Trends & Uncertainties:** - **Revenue Growth:** Positive trend driven by Jelmyto demand. - **Operating Expenses:** Increasing due to commercialization efforts and R&D activities. - **Cash Flow:** Negative cash flow from operations, offset by financing activities. **Future Operations Impact:** - **Commercialization:** Continued focus on Jelmyto and UGN-102. - **R&D:** Ongoing clinical trials and regulatory approval processes. - **Financing:** Reliance on equity and debt financings, collaborations, and product sales.